Journal
FUTURE MEDICINAL CHEMISTRY
Volume 2, Issue 10, Pages 1563-1576Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.10.241
Keywords
-
Categories
Funding
- Canadian Institutes for Health Research [1097737]
- Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute
- GlaxoSmithKline
- Karolinska Institutet
- Knut and Alice Wallenberg Foundation
- Ontario Innovation Trust
- Ontario Ministry for Research and Innovation
- Merck Co., Inc.
- Novartis Research Foundation
- Swedish Agency for Innovation Systems
- Swedish Foundation for Strategic Research
- Welcome Must
Ask authors/readers for more resources
Several 'classical' protein tyrosine phosphatases are attractive therapeutic targets, including PTPIB for obesity and Type II diabetes; SHP2 for cancer and Lyp for rheumatoid arthritis. Progress has been made in identifying a broad range of chemically distinct inhibitors; however, developing selective and cell-permeable clinically useful compounds has proved challenging. Here the ongoing challenges and recent significant advances in the field are reviewed. Key novel compounds are highlighted and a perspective on the future of phosphatase inhibitor development is presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available